Você está deixando o Portal Médico GSK

Você está prestes a deixar o site da GSK. Ao clicar neste link, você será direcionado a um site que não pertence ou é controlado pela GSK. Portanto, a GSK não é responsável por demais conteúdos presentes neste site.

Continuar

Voltar

Impactos da coqueluche em pacientes com DPOC e asma

Refortrix_GSKDC-BRA-PT-2017-30556_D4.indd
    
  • Referências bibliográficas

    1. CENTERS FOR DISEASE CONTROL AND PREVENTION. Pertussis. In: ____. Epidemiology and prevention of vaccine-preventable diseases. 12 ed. Atlanta: Public Health Foundation, 2012. v. 2, p. 261-278. Disponível em: <http://www.cdc.gov/vaccines/pubs/pinkbook/pert.html>. Acesso em: 01 Ago. 2017.

    2. BRASIL. Ministério da Saúde. Coqueluche no Brasil: análise da situação epidemiológica de 2010 a 2014. Boletim Epidemiológico, 49(39), 2015. 8p. Disponível em: <http:// portalsaude.saude.gov.br/images/pdf/2015/dezembro/08/2015-012---Coqueluche-08.12.15.pdf>. Acesso em: 01 Ago. 2017.

    3. SOCIEDADE BRASILEIRA DE IMUNIZAÇÕES. Pneumologia: guia de imunização SBIm/SBPT, 2014/15. Disponível em: <http://sbim.org.br/images/files/guia-pneumo-sbim-140925-141218-bx.pdf>. Acesso em: 01 Ago. 2017.

    4. XU, JF. et al. Bronchiectasis caused by pulmonary tuberculosis: The epidemiology, clinical presentations and the differences from non-tuberculosis-caused bronchiectasis. Eur Resp J, 42(Suppl 57): P2796, 2013.

    5. BORECKI, S. et al. The evaluation of epidemiological data and etiological reasons of bronchiectasis patients. Eur Respir J, 42(Suppl 57): P2207, 2013.

    6. CHERRY, J. Epidemiology of Pertussis. The Pediatric Infectious Disease Journal, 25(4): 361-362, 2006.

    7. CELENTANO, L. et al. Resurgence of Pertussis in Europe. Pediatr Infect Dis J, 24(9):S10–S18, 2005.

    8. ZEPP, F. et al. Rationale for pertussis booster vaccination throughout life in Europe. Lancet Infect Dis, 11(7):557–70, 2011

    9. STEFANOFF, P et al. Incidence of pertussis among patients with prolonged cough visiting general practitioners in Poland, 2009-2010: a prospective enhanced surveillance study. IN: 29th European Society of Pediatric Infectious Diseases, The Netherlands, 2011.

    10. WOOD, N. et al. Pertussis: review of epidemiology, diagnosis, management and prevention. Paediatr Respir Rev, 9(3):201–211, 2008.

    11. TAN, T. et al. Epidemiology of pertussis. Pediatr Infect Dis J, 24(5 Suppl):S10–S18, 2005.

    12. PESEK, R. et al. Vaccination of adults with asthma and COPD. Allergy, 66:25-31, 2011.

    13. CENTERS FOR DISEASE CONTROL AND PREVENTION. Lung Disease including Asthma and Adult Vaccination. Disponível em: https://www.cdc.gov/vaccines/adults/rec-vac/health-conditions/lung-disease.html>. Acesso em: 01 Ago. 2017.

    14. REFORTRIX® [vacina adsorvida difteria, tétano, pertussis (acelular)]. Bula do produto.

    15. GSK. GSK Clinical Study Register – Study 208355/050. Disponível em: <https://www.gsk-clinicalstudyregister.com/files2/a69cd0ca-21e3-46dc-84ec-99653d58f736>. Acesso em: 01 Ago. 2017.

    16. BOOY, R. A decennial booster dose of reduced antigen content diphtheria, tetanus, acellular pertussis vaccine (Boostrix) is immunogenic and well tolerated in adults. Vaccine, 29:45-50, 2011